newsfilter
← Latest News
GlobeNewswire·

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had